Last reviewed · How we verify

didanosine + lamivudine + efavirenz — Competitive Intelligence Brief

didanosine + lamivudine + efavirenz (didanosine + lamivudine + efavirenz) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Antiretroviral combination therapy (NRTI + NNRTI). Area: Infectious Disease / Virology.

marketed Antiretroviral combination therapy (NRTI + NNRTI) HIV reverse transcriptase Infectious Disease / Virology Small molecule Live · refreshed every 30 min

Target snapshot

didanosine + lamivudine + efavirenz (didanosine + lamivudine + efavirenz) — Clinical Trial Agency of HIV Study Group. This combination of three antiretroviral drugs inhibits HIV replication by blocking reverse transcriptase and integrase enzymes required for viral reproduction.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
didanosine + lamivudine + efavirenz TARGET didanosine + lamivudine + efavirenz Clinical Trial Agency of HIV Study Group marketed Antiretroviral combination therapy (NRTI + NNRTI) HIV reverse transcriptase
Once-daily ABC+3TC Once-daily ABC+3TC Medical Research Council marketed Nucleoside reverse transcriptase inhibitor (NRTI) combination HIV reverse transcriptase
Abacavir/Lamivudine Abacavir/Lamivudine GlaxoSmithKline marketed Nucleoside reverse transcriptase inhibitor (NRTI) HIV reverse transcriptase
Dolutegravir/Lamivudine as a single pill Dolutegravir/Lamivudine as a single pill Fundacion SEIMC-GESIDA marketed Antiretroviral combination (INSTI + NRTI) HIV integrase; HIV reverse transcriptase
nucleoside reverse transcriptase inhibitors nucleoside reverse transcriptase inhibitors French National Agency for Research on AIDS and Viral Hepatitis marketed Nucleoside reverse transcriptase inhibitor (NRTI) HIV reverse transcriptase
All licensed antiretroviral medications All licensed antiretroviral medications University of Minnesota marketed Antiretroviral agents (multiple classes: NRTIs, NNRTIs, PIs, INSTIs, entry inhibitors) Multiple (HIV reverse transcriptase, HIV protease, HIV integrase, CCR5, CXCR4, gp120/gp41)
AZT+3TC+IDV+RTV AZT+3TC+IDV+RTV Hospital Clinic of Barcelona marketed Antiretroviral combination therapy (NRTI + PI) HIV reverse transcriptase; HIV protease

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Antiretroviral combination therapy (NRTI + NNRTI) class)

  1. GlaxoSmithKline · 2 drugs in this class
  2. Clinical Trial Agency of HIV Study Group · 1 drug in this class
  3. Hospital Clinic of Barcelona · 1 drug in this class
  4. Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran · 1 drug in this class
  5. National Center for AIDS/STD Control and Prevention, China CDC · 1 drug in this class
  6. Peking Union Medical College Hospital · 1 drug in this class
  7. Sheba Medical Center · 1 drug in this class
  8. Azienda Ospedaliera San Gerardo di Monza · 1 drug in this class
  9. University of KwaZulu · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). didanosine + lamivudine + efavirenz — Competitive Intelligence Brief. https://druglandscape.com/ci/didanosine-lamivudine-efavirenz. Accessed 2026-05-18.

Build your own brief

Pick any drug + add comparators: